Checkpoint Trend (531099)

Score breakdown: P/E: 2/3 · ROCE: 1/2 · Growth: 2/2 · Dividend: 0/1

Key Financials

Strengths

• Latest quarter revenue of ₹174 Cr shows operating scale and a sharp improvement from a near-zero base.
• Piotroski F-Score of 7/9 indicates basic financial health across profitability, leverage, liquidity and efficiency.
• ROCE of 16.51% is reasonable, suggesting capital employed is generating positive returns.
• Positive net profit of ₹1 Cr after likely earlier losses hints at a possible business inflection.
• P/E of 17.5 is not extreme if the improved earnings prove sustainable.

Concerns

• Net profit margin is razor-thin: ₹1 Cr profit on ₹174 Cr sales is only about 0.6%, leaving no buffer for setbacks.
• P/B of 8.23 against a book value of ₹1.15 means the price has very little asset support.
• Current price of ₹9.46 is below the stated 52-week range of ₹28.22–₹144.40, suggesting unreliable or distorted data.
• Promoter holding, debt/equity, and dividend details are absent, creating a lack of transparency.

AI Analysis

Let me begin with a lesson from Graham: the market can quote a price, but it cannot quote a value. Checkpoint Trend is quoted at ₹9.46, a ₹5 crore market cap. The latest quarter shows ₹174 crore of sales and ₹1 crore of net profit—a net margin of barely 0.6%. The reported sales growth of 173,990% and profit growth of 1,000% sound astonishing, but when the starting base is near zero, percentages lose meaning. What the numbers really suggest is a turnaround: a ₹5 crore company with a stated P/E of 17.5 has trailing earnings of roughly ₹0.29 crore, meaning that the last quarter's ₹1 crore profit was offset by losses in earlier quarters. So I am being asked to value a company on one quarterly spurt. Book value is ₹1.15, so I'd be paying 8.2 times book. ROE of 399% is a red flag, not a trophy—it reflects a tiny equity base, not pricing power. ROCE of 16.51% is decent but not outstanding. The 52-week range of ₹28–₹144 doesn't even include today's price, so either the data is wrong or the stock has been through massive distortion. There is no promoter holding disclosed, no debt-to-equity disclosure, and no dividend. F-Score of 7/9 is a small positive, but I can't build an investment on one ratio. Where is the moat? In pharmaceuticals, you need regulatory approvals, quality systems, and a track record. I see none here. This is a speculation on a turnaround, not a value investment. One good quarter is not enough; I need consistency, transparency, and a margin of safety. I pass.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer